Machine learning in the prevention of heart failure.

Journal: Heart failure reviews
PMID:

Abstract

Heart failure (HF) is a global pandemic with a growing prevalence and is a growing burden on the healthcare system. Machine learning (ML) has the potential to revolutionize medicine and can be applied in many different forms to aid in the prevention of symptomatic HF (stage C). HF prevention currently has several challenges, specifically in the detection of pre-HF (stage B). HF events are missed in contemporary models, limited therapeutic options are proven to prevent HF, and the prevention of HF with preserved ejection is particularly lacking. ML has the potential to overcome these challenges through existing and future models. ML has limitations, but the many benefits of ML outweigh these limitations and risks in most scenarios. ML can be applied in HF prevention through various strategies such as refinement of incident HF risk prediction models, capturing diagnostic signs from available tests such as electrocardiograms, chest x-rays, or echocardiograms to identify structural/functional cardiac abnormalities suggestive of pre-HF (stage B HF), and interpretation of biomarkers and epigenetic data. Altogether, ML is able to expand the screening of individuals at risk for HF (stage A HF), identify populations with pre-HF (stage B HF), predict the risk of incident stage C HF events, and offer the ability to intervene early to prevent progression to or decline in stage C HF. In this narrative review, we discuss the methods by which ML is utilized in HF prevention, the benefits and pitfalls of ML in HF risk prediction, and the future directions.

Authors

  • Arsalan Hamid
    Division of Cardiology, Department of Medicine, Baylor College of Medicine, 6655 Travis Street, Suite 320, Houston, TX, 77030, USA. arsalan93@hotmail.com.
  • Matthew W Segar
    Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Biykem Bozkurt
    Michael E. DeBakey VA Medical Center & Baylor College of Medicine, Houston, TX (B.B., A.D.).
  • Carlos Santos-Gallego
    The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Vijay Nambi
    Department of Cardiology, Baylor College of Medicine, 77001, TX, USA.
  • Javed Butler
    Department of Medicine, University of Mississippi Medical Center, Jackson, MS.
  • Michael E Hall
    Department of Medicine, University of Mississippi Medical Center, Jackson (A.C., J.B., M.E.H.).
  • Marat Fudim
    Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC, USA.